share hit ms drug suspensshare elan biogen idec plung monday firm suspend sale new multipl sclerosi drug tysabri patient death usnew york stock exchang share irelandbas elan lost 70 us partner biogen idec 43 firm took action death central nervous system diseas suspect case condit case cite involv use tysabri avonex biogen idec exist multipl sclerosi drug compani said report rare condit  progress multifoc leukoencephalopathi pml  patient take either tysabri avonex alon tysabri approv use us last novemb wide tip becom world lead multipl sclerosi treatmentcompani will work clinic investig evalu tysabritr patient will consult lead expert better understand possibl risk pml two firm said statement outcom evalu will use determin possibl reiniti dose clinic trial futur commerci availanalyst believ product provid new growth opportun biogen idec face increas competit rival avonex elan biggest firm irish stock exchang also expect receiv boost new product inquiri elan account 2002 brought group close bankruptci firm rebuild sinc share price increas almost fourfold last year valu compani tysabri said ian hunter goodbodi stockbrok dublin now question mark elan finish 1890 8 biogen fell 2863 3865 share uk pharmaceut firm phytopharm close 1984 1515 penc london stock exchang monday said partner set pull deal experiment alzheim diseas treatment phytopharm said japan yamanouchi pharmaceut like end licens agreement prompt analyst rais question level futur cash reserv